Potassium Ion

Potassium Ion

SCHEMBL385052

O=C([O-])CN(CCCNC(=O)OCC1c2ccccc2-c2ccccc21)CCCNC(=O)OCC1c2ccccc2-c2ccccc21.[K+]

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA

The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.60
EPHX2 P34913 1/20 0.44
DOT1L Q8TEK3 1/20 0.41
TLR2 O60603 1/20 0.41
TLR1 Q15399 1/20 0.41
OPRD1 P41143 1/20 0.38
FABP7 O15540 1/20 0.38
FABP5 Q01469 1/20 0.38
CASP3 P42574 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfuric Acid SCHEMBL6026967 0.96 KMT2A (0.58) KMT2AEPHX2DOT1LTLR2TLR1
SCHEMBL260592 0.88 KMT2A (0.69) KMT2AEPHX2DOT1LOPRD1FABP7
Sulfuric Acid SCHEMBL3444552 0.87 KMT2A (0.61) KMT2AEPHX2DOT1LOPRD1CASP3
Sulfuric Acid SCHEMBL3444555 0.87 KMT2A (0.61) KMT2AEPHX2DOT1LOPRD1CASP3
SCHEMBL19450607 0.81 KMT2A (0.64) KMT2AEPHX2OPRD1FABP7FABP5
SCHEMBL230688 0.81 KMT2A (0.72) KMT2AEPHX2DOT1LFABP7FABP5
SCHEMBL31031901 0.81 KMT2A (0.72) KMT2AEPHX2DOT1LFABP7FABP5
SCHEMBL29468684 0.81 KMT2A (0.72) KMT2AEPHX2DOT1LFABP7FABP5
Potassium Ion SCHEMBL17079658 0.81 KMT2A (0.62) KMT2AEPHX2TLR2TLR1OPRD1
SCHEMBL793384 0.81 KMT2A (0.85) KMT2AEPHX2TLR2TLR1FABP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4169944-A1 PROCESS FOR PREPARING HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE Biomolecular Holdings LLC (US) 2023-04-26 EP disclosed
US-11572398-B2 GLP-1 derivatives and uses thereof NOVO NORDISK A/S (DK) 2023-02-07 US disclosed
US-20220275108-A1 HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE BIOMOLECULAR HOLDINGS LLC (US) 2022-09-01 US disclosed
EP-3701971-B1 COMPOUNDS USEFUL IN PREPARING HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE BIOMOLECULAR HOLDINGS LLC (US) 2022-07-06 EP disclosed
US-11220556-B2 Hybrid immunoglobulin containing non-peptidyl linkage BIOMOLECULAR HOLDINGS LLC (US) 2022-01-11 US disclosed
EP-3611180-B1 HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE BIOMOLECULAR HOLDINGS LLC (US) 2021-12-22 EP disclosed
US-20210340222-A1 HYBRID IMMUNOGLOBULIN CONTAINING NONPEPTIDYL LINKAGE BIOMOLECULAR HOLDINGS LLC (US) 2021-11-04 US disclosed
US-11066459-B2 Hybrid immunoglobulin containing non-peptidyl linkage BIOMOLECULAR HOLDINGS LLC (US) 2021-07-20 US disclosed
EP-3701971-A1 COMPOUNDS USEFUL IN PREPARING HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE Capon, Daniel J. (US) 2020-09-02 EP disclosed
EP-3611180-A1 HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE Capon, Daniel J. (US) 2020-02-19 EP disclosed
US-20170320927-A1 GLP-1 Derivatives and Uses Thereof NOVO NORDISK A/S (DK) 2017-11-09 US disclosed
EP-3226906-A1 GLP-1 DERIVATIVES AND USES THEREOF Novo Nordisk A/S (DK) 2017-10-11 EP disclosed
US-20170008950-A1 HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE BIOMOLECULAR HOLDINGS LLC 2017-01-12 US disclosed
WO-2016083499-A1 GLP-1 DERIVATIVES AND USES THEREOF NOVO NORDISK A/S (DK) 2016-06-02 WO disclosed
US-9012603-B2 Peptides that block the binding of IgG to FcRn BIOGEN IDEC HEMOPHILIA INC. (US) 2015-04-21 US disclosed
US-8906844-B2 Immunomodulatory peptides BIOGEN IDEC HEMOPHILIA INC. (US) 2014-12-09 US disclosed
US-8101186-B2 Peptides that block the binding of IgG to FcRn SYNTONIX PHARMACEUTICALS, INC. (US) 2012-01-24 US disclosed
US-20110230639-A1 IMMUNOMODULATORY PEPTIDES SYNTONIX PHARMACEUTICALS INC. (US) 2011-09-22 US disclosed
US-20110059889-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn SYNTONIX PHARMACEUTICALS, INC. 2011-03-10 US disclosed
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn BIOGEN HEMOPHILIA INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066459-B2 Hybrid immunoglobulin containing non-peptidyl linkage FCGR3B, FCGR2A, SCLY KMT2A 3227/4885EPHX2 667/4885DOT1L 3720/4885
US-20220275108-A1 HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE FCGR3B, FCGR2A, VSIG8 KMT2A 2199/4885EPHX2 388/4885DOT1L 2654/4885
US-11220556-B2 Hybrid immunoglobulin containing non-peptidyl linkage FCGR3B, FCGR2A, VSIG8 KMT2A 1597/4885EPHX2 457/4885DOT1L 1380/4885
US-20110059889-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn FCGRT, FCGR3B, FCGR1A KMT2A 4447/4885EPHX2 3220/4885DOT1L 4853/4885
US-20210340222-A1 HYBRID IMMUNOGLOBULIN CONTAINING NONPEPTIDYL LINKAGE FCGR3B, FCGR2A, SCLY KMT2A 3177/4885EPHX2 559/4885DOT1L 3719/4885
US-11572398-B2 GLP-1 derivatives and uses thereof GLP1R, GIPR, GCG KMT2A 4053/4885EPHX2 1828/4885DOT1L 4665/4885
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn FCGRT, FCGR3B, FCGR1A KMT2A 4447/4885EPHX2 3220/4885DOT1L 4853/4885
US-20170320927-A1 GLP-1 Derivatives and Uses Thereof GLP1R, GIPR, GCG KMT2A 4053/4885EPHX2 1828/4885DOT1L 4665/4885
US-20170008950-A1 HYBRID IMMUNOGLOBULIN CONTAINING NON-PEPTIDYL LINKAGE FCGR3B, SCLY, FCGR2A KMT2A 2998/4885EPHX2 766/4885DOT1L 3394/4885
US-20110230639-A1 IMMUNOMODULATORY PEPTIDES FCGRT, FCGR3B, FCGR2A KMT2A 2817/4885EPHX2 2888/4885DOT1L 2483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.